Bristol Myers Squibbb击败了Q3收入估算, 提升了2025年的指引, Bristol Myers Squibb beat Q3 earnings estimates, raised 2025 guidance, and raised its dividend.

Bristol Myers Squibb报告,Q3 2025年收入为每股163美元,增加估计数为11美元,收入为12.22亿美元,超过预测4.7亿美元。 Bristol Myers Squibb reported Q3 2025 earnings of $1.63 per share, beating estimates by $0.11, with revenue of $12.22 billion, exceeding forecasts by $470 million. 该公司将其2025年全年的EPS指南提高到6.40至6.60美元,指出Opdivo和Eliquis等肿瘤学和免疫学产品表现强劲。 The company raised its full-year 2025 EPS guidance to $6.40–$6.60, citing strong performance in oncology and immunology products like Opdivo and Eliquis. 股票交易额45.96美元,市场上限为935.5亿美元,在季度支付0.62美元后,股息收益为5.4%。 The stock, trading at $45.96 with a market cap of $93.55 billion, has a 5.4% dividend yield after a $0.62 quarterly payout. 机构所有权占76.41%,分析师保持了“稳住”共识评级,目标价格为57.23美元。 Institutional ownership stands at 76.41%, and analysts maintain a "Hold" consensus rating with a $57.23 target price.